



American Association of Clinical Endocrinology (AACE) 2026

April 22 - 24, 2026; Las Vegas, Nevada; Day #3 Highlights – Draft

Welcome to our resource hub for AACE 2026! This is a one-stop-shop for all your AACE 2026 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Table of Contents

[Day-of Conference Reports](#)

[Diabetes Highlights](#)

Day-of Conference Reports

1. [AACE 2026 Day #1 Highlights](#)
2. [AACE 2026 Day #2 Highlights](#)
3. [AACE 2026 Day #3 Highlights](#)

Diabetes Highlights

1. [Opening session](#) places nutrition at the center of AACE 2026 Annual Meeting
2. [Role of AI in diabetes care](#): Leveraging CGM-driven insights to support agentic recommendations
3. [Global perspectives from Pakistan, Mexico, and India](#) highlight diabetes heterogeneity and the need for context-specific care across regions
4. [Interdisciplinary strategies](#) to detect and treat “at-risk MASH”
5. [CKM discussion continues](#): Dr. Rodolfo Galindo emphasizes metabolic complexity and the need for standardized interpretation
6. [Dexcom product theater showcases CGM portfolio](#), evidence in non-insulin T2D, and Smart Basal titration platform
7. [Diabetes Year in Review](#): Treatment algorithm improvements for better care across T1D and T2D
8. [Dr. Michelle Look on exercise and nutrition](#) recommendations during GLP-1 RA/GIP therapy for obesity
9. [Cardiometabolic “Year in Review”](#): Evolving lipid therapy guidelines and cardiometabolic strategies for long-term risk reduction
10. [AACE’s prediabetes algorithm](#): Case studies to demonstrate efficacy
11. [Nutrition & Obesity Year in Review](#): Obesity care moves beyond BMI as pharmacologic options accelerate and nutrition remains foundational
12. [“Betting on basal”](#): Casino-themed night focused on how to improve odds for PWDs
13. [AACE 2026 algorithm update for adults with T2D](#): Expanding from glycemic management to a fully integrated cardiometabolic, complications-driven framework
14. [Dr. Viral Shah on the use of GLP-1 RAs for obesity](#) and cardiometabolic management in T1D
15. [To BMI or not to BMI](#): An outdated metric or an important assessment tool in the management of obesity?
16. [Weekly basal insulin debate](#): Adherence and simplicity in T2D weighed against hypoglycemia risk and physiologic mismatch in T1D

17. [CGM in gestational diabetes](#): Debate highlights clear benefits in high-risk patients, but mixed evidence limits broad adoption
18. [AID enters the T2D guidelines](#) as clinical trial and real-world data show rapid gains in TIR
19. [Addressing cardiovascular risk in T1D](#): Statins, non-statins, and beyond
20. [Dr. Linda DiMeglio on transforming early stage T1D](#) through screening and disease modifying therapies
21. [Disrupting the status quo of underdiagnosis](#) in hypercortisolism cases
22. [CGM and AID in the perioperative setting](#): Growing guideline support contrasts with variable real-world adoption
23. [Cell therapies in T1D move closer to clinic](#), as Breakthrough T1D CEO Dr. Aaron Kowalski outlines path to scalable cures
24. [Microdosing GLP 1 RAs](#) as a practical strategy amid access barriers
25. [Obesity as a multisystem disease](#): Why liver assessment is essential in metabolic care
26. [Lilly's Foundayo shows meaningful weight loss](#) and positions oral GLP-1 RAs for earlier obesity intervention
27. [Liver health](#): The new frontier in cardiometabolic management
28. [Madrigal product theater](#): The role of liver-directed therapy in MASLD/MASH
29. [Pediatric obesity management](#): Pharmacotherapy, surgery, and breaking down barriers